Sequencing Platform Development

About Daisy Genomics

Daisy Genomics is an early-stage biotech innovator building a next-generation sequencing platform designed to overcome the limitations of current NGS and nanopore methods. Its core technology leverages Surface-Enhanced Raman Spectroscopy (SERS) within proprietary nanochannels to directly read the chemical 'fingerprint' of individual nucleotides, enabling the detection of epigenetic marks and structural variants on ultra-long DNA strands without sample amplification. The company is pre-revenue and research-focused, having secured grant funding and partnerships to advance its platform for applications in research, diagnostics, and therapeutic development, with an initial focus on cancer.

Therapeutic Areas